Pharmaceutical companies and large pharmacies hold work analysis meeting in the first half of the year.
Release time:
2020-08-17
Joint Summary Joint Development
Pharmaceutical Company and Major Pharmacy Held First Half Work Analysis Meeting
News 7# August 21 , Jinhua Pharmaceutical Company and Jianfeng Major Pharmacy jointly held the first half work analysis meeting to summarize and analyze the work in the first half of 2020 , and the direction of joint management development in the future is discussed and studied. At the
meeting, Wu Weisheng, general manager of the pharmaceutical company, and Xiang Shunjiao, general manager of the large pharmacy, respectively reported on the main work of their respective companies in the first half of the year and the focus of work in the second half of the year, and focused on the existing problems and business risks faced, and put forward countermeasures and measures to solve them.Huang Jinlong, Deputy General Manager of the Group and General Manager of the Pharmaceutical Company, presided over the meeting, where he commented on the main work of the two companies in the first half of the year and praised and affirmed the contributions made by the two companies in the prevention and control of the new crown epidemic. At the same time, we encourage everyone to see more opportunities in the predicament, strengthen communication with the government drug supervision and other relevant departments, develop end customers in a targeted manner, broaden the sales network, increase market share, and increase business sales. In view of the actual situation of the current pharmaceutical industry market and the working ideas of the two companies in the second half of the year, Golden Dragon requires the two companies to strictly follow GSP
standards and government regulations, operate legally and in compliance, and always pay attention to control such as accounts receivable, taxation, Risks in drug inventory, labor and employment, etc.; strengthen and broaden the sales network, strengthen cooperation with industrial manufacturers and retail pharmacies, introduce varieties, and do a good job in promotion, increase market share; strengthen integration from internal management, procurement varieties, etc., share resources, and complement each other's advantages; give full play to the role of existing licensed pharmacists, guide and encourage employees to strengthen business learning, specialize in multiple abilities, improve personal business quality, and provide customers Provide more professional medical and pharmaceutical services; make full use of its own real estate resources to develop other businesses, revitalize idle fixed assets, and increase asset income. Jin Huazhong, Secretary of the Party Committee of
Pharmaceutical Company, attended the meeting. He asked the two companies to learn from the experience of brother companies in terms of job optimization, conduct job analysis and reasonable setting of organizational structures, personnel positions, etc., and give full play to the party, labor, and The functions of the league organization, care about and help employees solve practical problems, improve the level of employee welfare, during the high temperature period in summer, do a good job in preventing heatstroke and cooling for employees, especially front-line employees, to reflect the care of the party's labor organization for employees, so that the company can develop healthily, harmoniously and steadily. (Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page